-
BglII Restriction Endonuclease: Practical Use
2026-09-27
BglII Restriction Endonuclease (K3010) provides rapid cleavage of DNA containing its AGATCT recognition site, supporting plasmid DNA digestion, PCR product cleavage, and selected genomic DNA workflows. Use it when the target sequence and expected digest pattern are known; it is for research use only and is not intended for diagnostic or medical applications.
-
Palomid 529: ESCC Pathway Testing
2026-09-26
Use Palomid 529 (P529) as a downstream pathway probe to test whether PI3K/Akt/mTOR activity contributes to RCN2-associated cisplatin resistance in esophageal squamous cell carcinoma. The workflow pairs pathway readouts with drug-response, motility, and endothelial assays while keeping P529 distinct from a direct RCN2 inhibitor.
-
Partial BACE Inhibition and Synaptic Transmission
2026-09-26
Satir et al. tested whether BACE inhibitors can lower amyloid-beta secretion without disrupting neuronal synaptic transmission. In cultured rat cortical neurons, partial inhibition associated with less than a 50% reduction in Aβ secretion spared the measured transmission readout, whereas stronger inhibition reduced it—an important distinction for interpreting BACE inhibitor experiments and dose selection.
-
Diethylmaleate in GST and Redox Stress Workflows
2026-09-25
Use Diethylmaleate to test how glutathione-dependent defenses shape oxidative-stress responses and insecticide sensitivity. A GST-focused insect study provides a quantitative example, while the workflow below separates literature findings from practical starting conditions that require local optimization.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-25
Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture different aspects of anticancer drug response: net growth effects and cell killing. Its central practical contribution is to interpret these outcomes separately and consider their timing, rather than treating a single viability endpoint as a complete measure of drug activity.
-
MG-132 (Z-LLL-al) in Proteasome Assays
2026-09-24
Use MG-132 to test whether proteasomal degradation contributes to a protein change, apoptosis phenotype, or cell-cycle response—not as a stand-alone explanation of mechanism. This workflow connects a cardiac hypoxia study to practical inhibitor controls while emphasizing dose selection, timing, and off-target interpretation.
-
DZNep for Epigenetic Regulation Research
2026-09-24
Use DZNep to probe EZH2/PRC2-associated repression, H3K27me3 changes, and downstream effects on cell fate or survival—with dose and time-course controls that help distinguish target biology from broader methylation effects. The workflow connects acute myeloid leukemia and metabolic-disease assays to human pluripotent stem cell research while clarifying why DZNep is not a substitute for locus-specific chromatin restoration.
-
Ertapenem: From PBP Target to Resistance Assay
2026-09-23
Ertapenem sodium salt is more than a broad-spectrum antibacterial standard: it can anchor assays that connect PBP inhibition, susceptibility phenotypes, and carbapenemase-gene mobility. This article translates molecular and epidemiological evidence into practical experimental decisions.
-
Mubritinib (TAK 165): Assay Workflow Guide
2026-09-23
Mubritinib (TAK 165) is most informative when used as a mitochondrial complex I probe rather than treated only as a historical HER2 inhibitor. This workflow guide connects dose selection, OXPHOS measurements, apoptosis profiling, and target-engagement controls for resistant AML and KSHV-positive PEL models.
-
Mubritinib–Albumin Recognition and Complex I Biology
2026-09-22
The reference study maps how Mubritinib (TAK 165) interacts with human serum albumin using complementary spectroscopic, biochemical, and molecular docking approaches. It identifies a moderately affine, site I-centered interaction that alters albumin fluorescence, structure, and esterase-like activity, providing pharmacokinetic context for research on this mitochondrial complex I inhibitor.
-
Toremifene Citrate: Applied Research Workflows
2026-09-21
Build reproducible estrogen-receptor experiments with Toremifene Citrate, from receptor-binding and MCF-7 proliferation assays to translational tumor-model planning. This guide emphasizes formulation, concentration selection, exposure timing, comparative controls, and troubleshooting that improve interpretation across breast cancer research workflows.
-
CHIR-99021 Workflow for Neural Differentiation
2026-09-21
CHIR-99021 (CT99021) provides selective GSK-3α/β inhibition for controlling pluripotency, differentiation, and Wnt/β-catenin signaling. This workflow connects pathway activation with exon-aware TRIM46 assays, helping researchers distinguish neuronal fate changes from post-transcriptional regulation during axon formation.
-
Dronedarone (Multaq): Atrial-Selective Research Strategy
2026-09-20
A mechanistic and translational framework for using Dronedarone (Multaq) in atrial fibrillation, atrial flutter, and cardiac arrhythmia pharmacology research, with emphasis on SK-channel evidence, assay design, and exposure-aware interpretation.
-
Verteporfin in YAP-TEAD Lineage Assays
2026-09-19
Verteporfin and CL 318952 are examined here as carefully controlled perturbations for linking phototoxicity, p62-dependent autophagy, and YAP-TEAD-regulated lineage commitment. The article translates recent super-enhancer research into assay-design decisions for ocular, cancer, and developmental models.
-
ARCA Cy5 EGFP mRNA (5-moUTP) Workflow
2026-09-18
Build a quantitative delivery workflow that separates mRNA uptake from productive EGFP translation in mammalian cells. Cy5 cargo tracking, ARCA capping, and 5-methoxyuridine modification make this reagent especially useful for comparing lipid nanoparticles, emulsions, and other mRNA delivery systems.